Singapore: +65-85097465 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Zimbabwe: +263-735539685, 773876488


Clinical Trial News

Positive results from third and final pivotal Phase 3 study of brodalumab in patients with moderate-to-severe plaque psoriasis announced

Amgen and AstraZeneca have announced that AMAGINE-2(TM), a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis...

AG-120 in IDH1 mutated acute myeloid leukemia shows "dramatic" early phase 1 results

Results presented by University of Colorado Cancer Center investigator Daniel Pollyea, MD, MS, at the 26th European Organisation for Research and Treatment of Cancer Symposium in Barcelona show...

Artificial pancreas better than pump for managing type 1 diabetes

A trial of two types of external artificial pancreas shows they are both better at keeping glucose levels stable than conventional insulin pump treatment.

Promising results in Ebola vaccine safety trial

A phase 1 trial in 20 healthy adults shows that an experimental Ebola vaccine developed by NIAID/GSK appears safe, results in an immune response and is well tolerated.

New data from a pooled analysis shows improved overall survival for prostate cancer patients treated with FIRMAGON

New data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS) and prostate specific antigen progression free survival (PSA PFS) for...

Type 1 diabetes 'reversed' in human cells using GABA

Building on a previous study in which they reversed type 1 diabetes in mice, scientists report success in repeating the process in human beta cells transplanted into mice.

New York Hospital Queens seeks volunteers for long-term NIH trial comparing type 2 diabetes treatments

New York Hospital Queens (NYHQ) is looking for volunteers to participate in an ongoing clinical research study designed to determine which of four widely-used FDA-approved diabetes medications...

Results of new drug, ASP8273, show response in patients with treatment-resistant NSCLC

In a second presentation looking at new ways of treating non-small cell lung cancer (NSCLC) that has both the EGFR and T790M mutations, researchers tod the 26th EORTC-NCI-AACR1 Symposium on...

James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook